Cargando…

CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer Analysis

Background: CD161 is a promising immune checkpoint mainly expressed on natural killer (NK) cells and is essential for immunoregulatory functions. However, it remains obscure how CD161 correlates with immune infiltration and patient prognosis in pan-cancer. Methods: We employed HPA, TCGA, GTEx, TIMER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Wenrui, Luo, Cong, Li, Chenglong, Liu, Zhixiong, Liu, Fangkun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489134/ https://www.ncbi.nlm.nih.gov/pubmed/34659549 http://dx.doi.org/10.7150/jca.63236

Ejemplares similares

CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis
por: Ye, Wenrui, et al.
Publicado: (2021)

A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
por: Zhou, Xiaohan, et al.
Publicado: (2021)

Immune Checkpoint in Glioblastoma: Promising and Challenging
por: Huang, Jing, et al.
Publicado: (2017)

Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas
por: Luo, Cong, et al.
Publicado: (2021)

Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis
por: Ye, Wenrui, et al.
Publicado: (2022)

Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
por: Zhang, Jingwei, et al.
Publicado: (2022)

Heme Oxygenase-1 Predicts Risk Stratification and Immunotherapy Efficacy in Lower Grade Gliomas
por: Ye, Wenrui, et al.
Publicado: (2021)

A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy
por: Li, He, et al.
Publicado: (2022)

CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
por: Liu, Fangkun, et al.
Publicado: (2020)

LLT1-CD161 Interaction in Cancer: Promises and Challenges
por: Braud, Veronique M., et al.
Publicado: (2022)

CTLA-4 correlates with immune and clinical characteristics of glioma
por: Liu, Fangkun, et al.
Publicado: (2020)

A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment
por: Wen, Jie, et al.
Publicado: (2021)

CD161+ regulatory t cells in immune regulation
por: Duurland, Chantal, et al.
Publicado: (2014)

Percentages of CD4+CD161+ and CD4−CD8−CD161+ T Cells in the Synovial Fluid Are Correlated with Disease Activity in Rheumatoid Arthritis
por: Miao, Jinlin, et al.
Publicado: (2015)

Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma
por: Liu, Fangkun, et al.
Publicado: (2019)

Identification of CD161 expression as a novel prognostic biomarker in breast cancer correlated with immune infiltration
por: Weng, Miaomiao, et al.
Publicado: (2022)

BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment
por: Kone, Abdou-samad, et al.
Publicado: (2022)

Natural killer cell-related gene signature predicts malignancy of glioma and the survival of patients
por: Li, Chenglong, et al.
Publicado: (2022)

CD161-Expressing Human T Cells
por: Fergusson, Joannah R., et al.
Publicado: (2011)

Deoxythymidylate Kinase as a Promising Marker for Predicting Prognosis and Immune Cell Infiltration of Pan-cancer
por: Lan, Tianfeng, et al.
Publicado: (2022)

SLC26A4 correlates with homologous recombination deficiency and patient prognosis in prostate cancer
por: Luo, Cong, et al.
Publicado: (2022)

Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
por: Guo, Xinyu, et al.
Publicado: (2023)

Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma
por: Xu, Shengchao, et al.
Publicado: (2021)

Role of CD47 in tumor immunity: a potential target for combination therapy
por: Huang, Jing, et al.
Publicado: (2022)

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
por: Yang, Jing, et al.
Publicado: (2022)

CD161(+) Tconv and CD161(+) Treg Share a Transcriptional and Functional Phenotype despite Limited Overlap in TCRβ Repertoire
por: Duurland, Chantal L., et al.
Publicado: (2017)

A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
por: Luo, Cong, et al.
Publicado: (2021)

Cytotoxic CD161(−)CD8(+) T(EMRA) cells contribute to the pathogenesis of systemic lupus erythematosus
por: Xiong, Hui, et al.
Publicado: (2023)

Expression of m6A Regulators Correlated With Immune Microenvironment Predicts Therapeutic Efficacy and Prognosis in Gliomas
por: Xu, Shengchao, et al.
Publicado: (2020)

Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma
por: Cong, Tianhao, et al.
Publicado: (2022)

Expansion of mixed immune cells using CD3/CD161 co-stimulation for the treatment of cancer
por: Tsumura, Ryo, et al.
Publicado: (2023)

CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas
por: Xu, Shengchao, et al.
Publicado: (2021)

CD93 Correlates With Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis
por: Zhang, Zerui, et al.
Publicado: (2022)

Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia
por: Xu, Zi‐jun, et al.
Publicado: (2022)

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
por: Yan, Chi, et al.
Publicado: (2021)

Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy
por: Ma, Bo, et al.
Publicado: (2023)

The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma
por: Xie, Qu, et al.
Publicado: (2023)

Pan‐cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors
por: Jiang, Junjie, et al.
Publicado: (2021)

CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors
por: Deng, Boya, et al.
Publicado: (2018)

Pan-Cancer Analysis Reveals the Signature of TMC Family of Genes as a Promising Biomarker for Prognosis and Immunotherapeutic Response
por: Song, Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jq2dcj8esc8uil7s659f39jfes